Fecal Transplant Durable in IBS; Growth Hormone for NAFLD? Drug Use and DAA Activity

Fecal microbiota transplant for irritable bowel syndrome (IBS) led to high response rates versus placebo and showed durable benefit out to 3 years, a trial from Norway showed. (Gastroenterology)

Use of growth hormone in non-alcoholic fatty liver disease (NAFLD) decreased liver fat and inflammation, according to research presented at ENDO 2022, the annual meeting of the Endocrine Society. Catch up on MedPage Today's coverage of the meeting here.

Children with NAFLD have a higher risk for type 2 diabetes, and severity of liver histology was associated with its development. (Clinical Gastroenterology and Hepatology)

In treatment-naive hepatitis B, a serological profile involving the coexistence of hepatitis B surface antigen (HBsAg) and antibodies against HBsAg was rare but linked with severe liver fibrosis and cirrhosis, a study from China found. (JAMA Network Open)

For untreated patients with chronic hepatitis B virus (HBV) infection, adding the core protein inhibitor vebicorvir to entecavir (Baraclude) was safe and led to deeper reductions in HBV DNA, a placebo-controlled phase II trial found. (Journal of Hepatology)

Long-term adherence to oral antivirals was inversely associated with decompensation and mortality in patients with HBV-related cirrhosis, a population-based study from China found. (BMJ Open)

Crohn's disease patients who underwent emergent intestinal resection were more commonly treated with non-biologics postoperatively compared to those who underwent elective resections. (Gastro Hep Advances)

Real-world data from Spain found that active drug use among hepatitis C patients taking glecaprevir/pibrentasvir (Mavyret) was tied to lower sustained virologic response with the direct-acting antiviral. (Journal of Infection)

Comment